← Leaderboards
J. Edwin Blalock
University Of Alabama At Birmingham
$21,586,966
Attributed
$22,635,535
Total exposure
11
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$22,635,535 · 11
By mechanism
R01$12,554,201 · 8
R35$9,855,201 · 2
P01$226,133 · 1
Top collaborators
- Peter Castaldi4 shared
- Amit Gaggar4 shared
Most similar at University Of Alabama At Birmingham
Same institution · by research overlap
- Amit Gaggar$7,818,359
- David E Briles$11,417,266
- James Michael Wells$3,103,783
- Tanecia R Mitchell$3,300,989
- Champion Christdoss Selvakumar Deivanayagam$3,873,296
Others in their field
Top investigators on “Pathway Interactions”
- David Heimbrook · Leidos Biomedical Research, Inc.$202,777,247
- Ralph Parchment · Leidos Biomedical Research, Inc.$146,974,543
- David R. Weir · University Of Michigan At Ann Arbor$129,316,139
- Daniel Ernest Ford · Johns Hopkins University$108,075,637
- David W Simpson · University Of Southern California$88,046,235
- Charles D. Blanke · Oregon Health And Science University$86,571,896
Research focus
Pathway InteractionsInflammationCollagenChronicNeutrophilIl8 GeneChronic Obstructive Airway DiseasePeptide HydrolasesLeadProlyl OligopeptidaseIn VitroAnimalsSmokingAcuteMouse ModelGenerationsNovel TherapeuticsPeptidesEnzymesAlveolarGlycineImmuneMetalloproteasesBiological Markers
Grant awards (48)
Pathogenic Exosomes in COPD$1,026,066
R35 · FY2025 · HL · contact PI
Pathogenic Exosomes in COPD$1,005,543
R35 · FY2024 · HL · contact PI
Pathogenic Exosomes in COPD$1,026,066
R35 · FY2023 · HL · contact PI
A Novel Exosomal Inflammatory Pathway$877,566
R35 · FY2023 · HL · contact PI
A Novel Exosomal Inflammatory Pathway$877,566
R35 · FY2022 · HL · contact PI
A Novel Exosomal Inflammatory Pathway$182,101
R35 · FY2022 · HL · contact PI
A Novel Exosomal Inflammatory Pathway$1,059,667
R35 · FY2021 · HL · contact PI
A Novel Exosomal Inflammatory Pathway$1,059,667
R35 · FY2020 · HL · contact PI
A Novel Exosomal Inflammatory Pathway$877,566
R35 · FY2019 · HL · contact PI
A Novel Exosomal Inflammatory Pathway$108,261
R35 · FY2019 · HL · contact PI
A Novel Exosomal Inflammatory Pathway$877,566
R35 · FY2018 · HL · contact PI
Genetics of Smoke-Altered LTA4H in COPD$390,354
R01 · FY2018 · HL · contact PI
A Novel Exosomal Inflammatory Pathway$877,566
R35 · FY2017 · HL · contact PI
Genetics of Smoke-Altered LTA4H in COPD$390,354
R01 · FY2017 · HL · contact PI
Genetics of Smoke-Altered LTA4H in COPD$390,354
R01 · FY2016 · HL · contact PI
HL-A New Pathway for Neutrophil-induced Airway Inflammation$367,500
R01 · FY2016 · HL · contact PI
Acquired LTA4H Dysfunction in COPD$492,831
R01 · FY2015 · HL · contact PI
Genetics of Smoke-Altered LTA4H in COPD$401,792
R01 · FY2015 · HL · contact PI
PGP, A Possible Biomarker for COPD Exacerbations and or Progression$366,250
R01 · FY2015 · HL · contact PI
Acquired LTA4H Dysfunction in COPD$490,329
R01 · FY2014 · HL · contact PI
PGP, A Possible Biomarker for COPD Exacerbations and or Progression$366,250
R01 · FY2014 · HL · contact PI
Acquired LTA4H Dysfunction in COPD$476,320
R01 · FY2013 · HL · contact PI
PGP, A Possible Biomarker for COPD Exacerbations and or Progression$366,250
R01 · FY2013 · HL · contact PI
A New Pathway for Neutrophil-induced Airway Inflammation$345,227
R01 · FY2013 · HL · contact PI
Acquired LTA4H Dysfunction in COPD$500,335
R01 · FY2012 · HL · contact PI
PGP, A Possible Biomarker for COPD Exacerbations and or Progression$366,250
R01 · FY2012 · HL · contact PI
A New Pathway for Neutrophil-induced Airway Inflammation$362,633
R01 · FY2012 · HL · contact PI
A New Pathway for Neutrophil-induced Airway Inflammation$362,633
R01 · FY2011 · HL · contact PI
Therapeutics for Chronic Lung Diseases: Antagonists of PGP, Chemokines and CXCR$411,690
R01 · FY2010 · HL · contact PI
A New Pathway for Neutrophil-induced Airway Inflammation$366,295
R01 · FY2010 · HL · contact PI
Effect of Macrolide Treatment on a Novel Pathway of Neutrophilic Inflammation in$362,500
R01 · FY2010 · HL · contact PI
Therapeutics for Chronic Lung Diseases: Antagonists of PGP, Chemokines and CXCR$411,364
R01 · FY2009 · HL · contact PI
Effect of Macrolide Treatment on a Novel Pathway of Neutrophilic Inflammation in$362,500
R01 · FY2009 · HL · contact PI
A New Pathway for Neutrophil-induced Airway Inflammation$353,201
R01 · FY2009 · HL · contact PI
Effect of Macrolide Treatment on a Novel Pathway of Neutrophilic Inflammation in$42,413
R01 · FY2009 · HL · contact PI
Effect of Macrolide Treatment on a Novel Pathway of Neutrophilic Inflammation in$362,500
R01 · FY2008 · HL · contact PI
A New Pathway for Neutrophil-induced Airway Inflammation$353,201
R01 · FY2008 · HL · contact PI
Effect of Macrolide Treatment on a Novel Pathway of Neutrophilic Inflammation in$362,500
R01 · FY2007 · HL · contact PI
A New Pathway for Neutrophil-induced Airway Inflammation$353,201
R01 · FY2007 · HL · contact PI
A New Pathway for Neutrophil-induced Airway Inflammation$363,750
R01 · FY2006 · HL · contact PI
Epithelial Ca2+ Channels:Therapeutic Targets in Asthma$424,760
R01 · FY2005 · HL
Epithelial Ca2+ Channels:Therapeutic Targets in Asthma$358,750
R01 · FY2004 · HL
Epithelial Ca2+ Channels:Therapeutic Targets in Asthma$51,660
R01 · FY2004 · HL
Epithelial Ca2+ Channels:Therapeutic Targets in Asthma$358,750
R01 · FY2003 · HL
Epithelial Ca2+ Channels:Therapeutic Targets in Asthma$358,750
R01 · FY2002 · HL
IMMUNOTHERAPY OF MYASTHENIA GRAVIS$233,783
R01 · FY2001 · AI
IMMUNOTHERAPY OF MYASTHENIA GRAVIS$226,971
R01 · FY2000 · AI
MOLECULAR STUDIES OF AN IMMUNE NETWORK IN AUTOIMMUNE DEMYELINATING DISEASE$226,133
P01 · FY2000 · NS